Abstract 1771
Background
Early tumor shrinkage (eTS) of 10% has been identified as a putative prognostic marker in mRCC, which could serve as an early read-out in clinical trials. We aimed to validate the prognostic role of eTS in first line TKI treatment using data from the COMPARZ study (NCT00720941).
Methods
A retrospective analysis on data of 1100 1st line patients treated with sunitinib or pazopanib was performed. Tumor response was measured according to RECIST 1.1. eTS was a priori defined as tumor shrinkage by ≥10%. The Kaplan-Meier method was used to estimate time-to-event outcomes. A landmark analysis was performed on day (d) 42 and d 90 after randomization. Cox proportional hazards regression was performed to evaluate the effect of prognostic factors on overall survival after d 42 and d 90.
Results
ConclusionsSimilar results were found for eTS at the 42 and 90 days landmarks. eTS ≥10% has prognostic relevance in mRCC and reflects a valid early endpoint in clinical trials. Clinical trial identificationNCT00720941 Legal entity responsible for the studyGSK sponsored study. Current analysis is retrospective on the initial data set. FundingMedical School Hannover, McMaster University DisclosureV. Grünwald: Honoraria: Novartis, Pfizer, BMS Consultation: Novartis, Pfizer, BMS. All other authors have declared no conflicts of interest. Resources from the same session4162 - Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT studyPresenter: Edward Wolin Session: Poster Display Resources: Abstract 3975 - Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE)Presenter: Martyn Caplin Session: Poster Display Resources: Abstract 4163 - Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label studyPresenter: George Fisher Jr Session: Poster Display Resources: Abstract 936 - Retrospective analysis of the efficacy of somatostatin analogs (SSA) in metastatic pulmonary neuroendocrine tumors and prognostic significance of FDG-PETPresenter: Alberto Bongiovanni Session: Poster Display Resources: Abstract 4213 - Role of somatostatin analogs(SSA)in combination with targeted agents(TTA)for neuroendocrine tumors(NETs)A systematic reviewPresenter: Miguel Beltran Session: Poster Display Resources: Abstract 2684 - Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)Presenter: Rossana Berardi Session: Poster Display Resources: Abstract 2730 - Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR studyPresenter: Jaume Capdevila Session: Poster Display Resources: Abstract 2073 - Efficacy and safety of targeted agents for treatment of gastroenteropancreatic (GEP) neuroendocrine tumor (NET)Presenter: Heejung Chae Session: Poster Display Resources: Abstract 1451 - Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trialPresenter: Tim Meyer Session: Poster Display Resources: Abstract 3945 - Progressing G1-G2 neuroendocrine tumors (WD NET) in treatment with capecitabine (Cp) plus somatostatin analog (SSA): a single center experiencePresenter: Riccardo Marconcini Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||
|---|---|---|---|